Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the <i>Mecp2-</i>Deficient Mouse Model.

Cells · 2026 · PMC12897355 · PMID 41677636

Europe PMC DOI

hedged sentences

0.0018

closest p · 0.0× alpha

0.0997

boldest claim

The sentences

highly significantp = 0.0018actually significant

The difference between the two treatments in the cortex was highly significant ( p = 0.0018).

also in 132,142 other papers

a numerical trendp = 0.0997so close (0.05 < p ≤ 0.1)

While the 0.3 mg/kg dose showed a numerical trend toward reduction, it did not consistently meet the threshold for significance across our replicates ( p = 0.0997).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the &lt;i&gt;Mecp2-&lt;/i&gt;Deficient Mouse Model.

The sentences

Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the <i>Mecp2-</i>Deficient Mouse Model.